MaxLinear MXL
Technology · Semiconductors · Synthos Deep Dive · 2026-07-06
The Overview
MaxLinear designs communication chips — the radio-frequency and signal-processing silicon inside cable/fiber modems, Wi-Fi routers, 5G infrastructure gear, and optical transceivers. It's a small company (~1,115 employees, Carlsbad, CA) that had a brutal 2023–24 downturn: revenue halved and it lost money for three straight years.
The business is now clearly recovering — sales have grown every quarter for over a year, and analysts expect ~40% revenue growth this year. The catch: the stock did not just recover, it went up roughly six-and-a-half times in twelve months, from around $13 to $96. That is far ahead of what the recovery itself justifies: Wall Street's own average price target is $69, a quarter below today's price, and the company still loses money under standard accounting.
Here's what our three scores mean in everyday terms:
- Downside Risk 9/10 (very high). The stock swings about four times as hard as the market, is priced at 17 times sales for a loss-making business, and sits above what even bullish analysts say it's worth. If sentiment turns, there is a long way down.
- Growth Quality 4/10 (below average). The recovery is real, but it's a recovery — not yet a proven, profitable growth engine. R&D eats 40 cents of every revenue dollar and returns on capital are still negative.
- Exponential Potential 4/10 (low-moderate). The forecasts say growth slows from here, and even in 2028 revenue would still be below its 2022 high. The share price is behaving like an exponential; the estimates are not.
The one big worry: the market is clearly betting on something bigger than what's in the published forecasts. If that bigger story doesn't materialize on schedule, a stock this expensive and this volatile can give back a very large share of its gains very quickly.
Putting a number on it: our fair-value estimate is $70 against a current price of $61.73 — real upside if our numbers are right.
Our summary metrics
Beta 3.93, 17× EV/sales on a GAAP-loss business, price 38% above the Street's own target, +557% 12-mo momentum, tangible book ~$1/share vs a $96 stock — near the top of the risk scale.
Five straight quarters of sequential revenue growth and 57% gross margin, but GAAP losses three years running, ROIC −13%, R&D 40% of revenue, SBC 10% of revenue — a recovery, not yet a quality grower.
Consensus growth decelerates (+40% 2026E → +20% 2027E → +11% 2028E) and 2028E revenue ($875M) is still below the FY2022 peak ($1.12B) — the stock is priced like an exponential; the published estimates describe a cyclical recovery.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Consensus growth decelerates (+40% 2026E → +20% 2027E → +11% 2028E) and 2028E revenue ($875M) is still below the FY2022 peak ($1.12B) — the stock is priced like an exponential; the published estimates describe a cyclical recovery.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $69.29 target (high $110 / low $30; 11 Buy · 6 Hold · 0 Sell) — the stock trades 38% above it |
| Valuation | P/E n.m. (TTM EPS −$1.51) · ~72× 2026E · 51× 2027E · 46× 2028E (non-GAAP est.) · EV/S 17.0× · P/B 18.5× · FCF yield ~0.1% |
| Technicals | Extended — $96, −25% off the 52-wk high ($128), 200-DMA at $35, RSI 55, +557% 12-mo (SPY +21%) |
| Conviction | Low — 0 KB claims, 0 expert voices; fundamentals-only note on a screen-surfaced name |
| Position sizing | None for now — if entered after a reset, speculative sleeve only, ≤0.5–1% |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for MXL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $61.73, 23% below the 50-day average ($80), 33% above the 200-day average ($46) — a mixed trend. 52% below the 52-week high of $128, 373% above the 52-week low of $13.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $61.73 is currently inside the band (band $57–$83).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 41.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.62, negative momentum.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = MXL · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
MaxLinear (Nasdaq: MXL) is a fabless communications systems-on-chip company. Its products integrate RF, high-performance analog/mixed-signal, DSP, security engines, data compression, networking layers, and power management — used in 4G/5G base-station and backhaul radios, optical transceivers, Wi-Fi and wireline routers, DOCSIS/PON/DSL broadband modems, and power-management/interface products. It sells through distributors, module makers, OEMs and ODMs; disclosed collaborations include Edgecore Networks (enterprise/SMB network infrastructure) and GCT Semiconductor (5G fixed-wireless-access gateways). Incorporated 2003, IPO 2010, headquartered in Carlsbad, CA; CEO Kishore Seendripu (founder); ~1,115 employees. Calendar fiscal year.
Revenue mix (FY2025, from filings):
- Broadband $204.4M (44%) — up +75% from FY2024's $116.8M; the biggest recovery engine.
- Infrastructure $148.2M (32%) — up +30% YoY (FY24 $113.9M); this is where the 5G/optical-transceiver story lives.
- Connectivity $78.0M (17%) — up +40% YoY.
- Industrial & multi-market $37.1M (8%) — down ~50% YoY; still shrinking.
Geography: the data file's geographic segmentation is stale (latest FY2018: Asia ~$313M of $385M ≈ 81% of revenue). We flag rather than extrapolate — but historically this has been an overwhelmingly Asia-shipped business, a real supply-chain/geopolitical exposure.
2. The expert thesis — why the panel is bullish (traceable)
No expert-panel coverage — this note is fundamentals-driven. A search of the Synthos KB returns zero MXL claims: no bullish voices, no bearish voices, no management-guidance ingestion. This name entered coverage via the quant momentum screen, not the conviction track.
What that means, honestly:
- There is no high-skill voice underwriting the story here, unlike our conviction names. Whatever narrative is powering a +557% twelve-month move (the market appears to be pricing an infrastructure/optical acceleration well beyond published consensus), our dataset contains no evidence for it — and we will not manufacture a thesis to fit the chart.
- The conviction rating is therefore Low by construction, the verdict is held to the conservative end, and the bear case in §3 is built entirely from the fundamentals and the quant screen.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 9 · Very high | Beta 3.93. 17.0× EV/sales and 18.5× book for a business with negative TTM EBITDA (−12% margin) and a −26% net margin. Price sits 38% above the Street's $69.29 consensus target. Tangible book value is ~$1.02/share vs a $96 stock. FCF ~$7M FY25 (yield ~0.1%). The only mitigants: modest net debt ($83M) and a 1.7× current ratio. |
| Growth Quality | 4 · Below average | The recovery is real — revenue +29.7% FY25, +43% YoY in Q1 2026, five straight sequential up-quarters, gross margin 57.0% TTM. Against it: GAAP losses in each of the last three years, ROIC −12.7%, income quality −0.17, R&D 40.5% and SBC 10.4% of revenue, and 2028E revenue still below the FY2022 peak. |
| Exponential Potential | 4 · Low-moderate | Consensus revenue growth decelerates: +40.5% (2026E) → +20.4% (2027E) → +10.6% (2028E). The 2nd derivative is negative — the opposite of the accelerating profile we score highly. An $8.6B cap leaves size-room, and the optical/5G infrastructure segment is the live optionality, but the published numbers describe a cyclical recovery, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path; the cases bound the range.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | The infrastructure/optical ramp forces major upward revisions — 2028E non-GAAP EPS well above the current $2.10 consensus — and the market pays ~50× on ~$2.10+ of demonstrated power. Matches the Street-high $110 target. | ~$110 (+15%) |
| Base (our anchor) | Estimates roughly hit — non-GAAP EPS $1.34 (2026E) → $1.875 (2027E) → $2.10 (2028E); a recovering but decelerating small-cap semi earns ~35× 2027E / ~33× 2028E. This lands almost exactly on the Street's $69.29 consensus, which we adopt as the anchor. | ~$70 (−27%) |
| Bear | Momentum unwinds and/or the ramp stalls; the market re-rates MXL as a GAAP-loss cyclical at ~19× 2027E non-GAAP EPS — near the Street-low $30 target. | ~$35 (−63%) |
Synthos fair value = the base case, ~$70 (−27%), with the full $35–$110 span as the honest range. The uncomfortable headline: even our bull case offers only +15% from here, while the base case is −27% and the bear −63%. That asymmetry — not the business, which is genuinely recovering — is why the verdict is Watch. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders from exponentials (accelerating, multi-baggers-from-here). MXL's share price behaved like an exponential (+557% in 12 months); its estimates do not:
- Forward growth: consensus revenue $657M (2026E) → $792M (2027E) → $875M (2028E); non-GAAP EPS $1.34 → $1.875 → $2.10 (2027E EPS +40%, 2028E +12%).
- Acceleration (the 2nd derivative) is negative: revenue growth +29.7% (FY25 actual) → +40.5% (2026E) → +20.4% (2027E) → +10.6% (2028E). After this year's recovery spike, the Street models rapid deceleration. That is what caps the score.
- Room to run — the honest nuance: 2028E revenue of $875M is still below the FY2022 peak of $1.12B, i.e. consensus models an incomplete cyclical recovery, not a new S-curve. At $8.6B the cap is small enough to multiply if a genuine new curve (optical transceivers, 5G FWA, Wi-Fi 7) emerges — that optionality, plus Infrastructure's +30% FY25 growth, is why this scores 4 and not 2.
- Reinvestment: capex is light (~2.4% of revenue TTM) but FCF is only ~$7M — the model scales cheaply, yet there is very little cash compounding today.
Exponential Potential: Low-moderate (4/10). The market is paying an exponential's price for a recovery's numbers. If the estimates are wrong to the upside, the score rises — but we score the data we have, not the chart.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY2025 $467.6M, +29.7% (FY24 $360.5M, which was −48.0% vs FY23 $693.3M; the FY22 peak was $1.12B). A severe downcycle, now recovering.
- Quarterly trajectory (the recovery is real): Q1'25 $95.9M → Q2 $108.8M → Q3 $126.5M → Q4 $136.4M → Q1'26 $137.2M (+43.0% YoY). Five consecutive sequential up-quarters; Street models Q2'26 at ~$164.6M (+51% YoY).
- Margins: gross 57.0% TTM (healthy for a fabless mixed-signal house), but operating margin −15.9% TTM and EBITDA margin −11.9% TTM — the P&L is still upside-down on a GAAP basis because R&D runs at 40.5% of revenue and SG&A at 32.3%.
- Earnings quality — read carefully. FY25 GAAP net loss −$136.7M / EPS −$1.58; Q1'26 GAAP loss −$45.1M (−$0.52) was inflated by a $26.5M tax charge against only a −$18.7M pretax loss — a one-off tax item, not operations. The Street tracks non-GAAP EPS, where MXL is profitable and beating: Q3'25 $0.14 (est $0.12), Q4'25 $0.19 (est $0.18), Q1'26 $0.22 (est $0.18). The GAAP↔non-GAAP gap (~$0.74/quarter) is mostly SBC (10.4% of revenue) and amortization — real costs; income-quality ratio −0.17 confirms cash income lags accounting adjustments.
- Cash flow: FY25 operating CF $19.6M, capex −$12.6M, FCF $7.0M (vs FY24 FCF −$63.0M and the FY22 peak of +$347M). Positive again, but thin — ~0.1% FCF yield at this price.
- Balance sheet: cash $74.2M, total debt $157.3M → net debt $83.1M; current ratio 1.70. Manageable, not fortress. 46% of total assets are goodwill + intangibles ($367.5M of $796.4M); retained earnings −$500M; tangible BVPS ~$1.02.
6. Valuation — priced in or room?
There is no honest way to anchor MXL on trailing numbers: P/E is not meaningful (TTM EPS −$1.51), EV/EBITDA is negative, and the sales-based multiples are extreme — 17.0× EV/sales, 16.8× P/S, 18.5× P/B — for a business with a −26% net margin. FMP's letter rating is C (overall 2/5; ROE and ROA score 1/5). On forward non-GAAP consensus the stock trades ~72× 2026E ($1.34) → ~51× 2027E ($1.875) → ~46× 2028E ($2.10) — and unlike a true hypergrower, the denominator is only compounding ~25%/yr off 2026, so the multiple does not melt quickly. The starkest fact in the file: the Street's consensus target is $69.29 (high $110, low $30, median $60) — the stock trades 38% above consensus and even above the median analyst's bull-adjacent view. Data caveat, flagged honestly: FMP's consensus EBITDA/EBIT estimates are negative through 2028 while net-income estimates are positive — a GAAP/non-GAAP basis mix in the feed; we rely on the EPS line (the standard non-GAAP convention) and treat the EBITDA rows as unreliable. Verdict on price: overvalued on every anchor the data provides — the market is paying today for revisions that have not yet been published.
7. Technicals (from the tech block)
- Trend: violently up. $95.68 sits above the 50-DMA ($86.81) and 2.7× the 200-DMA ($34.94) — a parabolic, not merely rising, trend structure.
- Location: −25.3% off the 52-week high ($128.03) — that is also the max drawdown from peak — and +633% off the 52-week low ($13.05). The stock has already had its first real shakeout from the January-area highs.
- Momentum: RSI(14) 55 — neutral; MACD +5.9 (positive). The froth of the highs has cooled without breaking the uptrend.
- Relative strength (the tell): +557% 12-mo vs SPY +21% and QQQ +31%; +432% 3-mo vs SPY +15% / QQQ +24%. This is one of the most extreme relative-strength profiles a screen can produce — leadership, but also maximal banked expectations.
- Read: technically extended. A 200-DMA nearly two-thirds below price means trend-followers have no meaningful support until far lower; the constructive scenario is a long sideways base above the 50-DMA ($87). For a Watch-verdict name, the levels that matter are ~$87 (50-DMA holding = story intact) and ~$70 (our base fair value / Street consensus = where valuation risk-reward turns acceptable).
8. Moat & competitive position
MaxLinear's edge is integration breadth in mixed-signal communications silicon — combining RF, analog, DSP, security and power management on single SoCs across broadband (DOCSIS/PON/DSL), Wi-Fi, 5G transport, and optical interconnect. The 57% gross margin says customers pay for that integration. But the honest read is a narrow-to-no moat at elite level: it competes against far larger, better-capitalized rivals across every line (Broadcom in broadband/Wi-Fi, Marvell in optical DSP and infrastructure), its FY22 boom-to-FY24 bust (revenue −48% in one year) shows weak pricing/backlog protection through a cycle, and ROIC is negative. Partnerships (Edgecore, GCT Semiconductor for 5G FWA) are optionality, not proof.
Peer set (FMP-supplied, market cap): a mixed and largely unhelpful list — Ultra Clean $4.7B, nLIGHT $3.7B, Fastly $2.9B, Cohu $2.8B, Himax $2.5B, Photronics $1.7B, Amplitude $1.2B, Alpha & Omega Semi $1.1B, indie Semi $1.0B, Alight $0.4B. The relevant comparators (Broadcom, Marvell, Semtech, Credo) are not in the supplied set — judge MXL against the communications-semi cohort, not this list. Notably, at $8.6B MXL is now larger than every peer FMP supplied, entirely on multiple expansion.
9. Management, capital allocation & guidance
- Leadership: founder-CEO Kishore Seendripu has run the company since 2003 — genuine domain depth and skin in the game, and he has steered it through multiple cycles including the 2023–24 collapse.
- Capital allocation: FY25 was survival-mode discipline — $20M of buybacks, no dividend, capex held to $12.6M (~2.7% of revenue), net debt kept modest at $83M. No acquisitions in FY25 (the goodwill on the books is legacy). Sensible for the balance sheet; note the buyback was executed at far lower prices than today's.
- Insider activity: the most recent discretionary transaction is director Thomas Pardun selling 11,000 shares at $105.00 (2026-05-26) — a sale within ~18% of the all-time high. Other May filings (Kwong, Moyer, Sennesael, Artusi) are routine RSU vesting/tax-withholding and director awards. One director sale near the top is a mild negative tell, not a mass exit.
- Guidance: the data file contains no ingested management guidance (no earnings-transcript block for MXL on our plan). The forward frame here is analyst consensus only — flagged as a coverage gap.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2 2026; Street EPS $0.33 non-GAAP, revenue ~$164.6M, +51% YoY). The key lines: Infrastructure segment growth (the optical/5G story the price implies) and whether gross margin holds ~57% through the ramp.
- Estimate revisions — the whole ballgame. The stock only "works" from $96 if 2027–28 consensus ($792M/$875M revenue, $1.88/$2.10 EPS) is revised sharply higher. Watch the revision tape after each print.
- Broadband cycle durability: Broadband drove FY25 (+75%); cable/PON operator capex is lumpy — a pause hits the biggest segment.
- Momentum/flows: with a 3.93 beta and +557% trailing return, MXL trades on positioning as much as fundamentals; a small-cap momentum rotation is itself a catalyst (down).
- Street-target convergence: either analysts chase the price up (targets rising toward $96+) or the price converges down toward $69 — the gap will close one way or the other.
Thesis tripwires (what would change the call): two consecutive quarters of sequential revenue decline; gross margin below ~54%; Infrastructure segment rolling over; or — on the upside — consensus 2027E revenue revised above ~$950M, which would force us to re-score Exponential Potential.
11. Key risks
- Valuation / momentum unwind (the dominant risk): 17× EV/sales, 46–72× forward non-GAAP earnings, and a price 38% above Street consensus, on a 3.93-beta stock up 6.5× in a year. If sentiment turns, the first fundamental valuation shelf (our ~$70 base) is 27% below, and the bear case is −63%.
- GAAP loss-making: three straight years of net losses; the profitability story rests entirely on non-GAAP adjustments (SBC alone is 10.4% of revenue). Dilution is the quiet cost — share count rose from 83.6M to 87.6M in five quarters.
- Cyclicality (demonstrated, not hypothetical): revenue fell 48% in FY2024. This business has already shown what its downcycle looks like.
- Deceleration risk: consensus itself models growth fading to +11% by 2028 — even hitting the numbers may not sustain the multiple.
- Competition: Broadcom, Marvell and other giants overlap every product line with deeper pockets and stronger customer lock-in.
- Concentration/geography: historically ~80% Asia-shipped (stale FY2018 data — flagged); supply-chain and export-policy exposure is real even if unquantified in current filings we hold.
- Coverage gap: no expert-panel voices, no ingested management guidance, unreliable consensus EBITDA rows — the information base under this note is thinner than for conviction names, which is itself a risk.
12. Verdict, position sizing & monitoring
Watch. The business deserves respect: five straight sequential up-quarters, +43% YoY revenue growth, 57% gross margin, positive non-GAAP EPS with three consecutive beats, a founder-CEO, and a manageable balance sheet. But the stock has traveled ~6.5× in twelve months to a price 38% above the Street's own consensus target, on published estimates that decelerate to +11% growth by 2028 with revenue still below the 2022 peak — and there is no expert voice in our KB underwriting the bigger story the price implies. Paying 17× sales for a GAAP-loss cyclical on momentum alone is not a Synthos trade. We would rather miss the next leg than underwrite this asymmetry (−27% to base, +15% to bull).
- Sizing: no position now. If the name resets toward ~$70 (base fair value / Street consensus) with the sequential-growth streak intact, it becomes a legitimate speculative-sleeve candidate at ≤0.5–1% — sized for a 3.93-beta stock where a 60% drawdown is within historical behavior.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-23). If consensus 2027–28 estimates are revised materially higher, the Exponential score and verdict get honestly revisited — upgrades are as trackable as downgrades. This verdict is logged as a tracked Synthos call as of 2026-07-06 at $95.68.
- Single biggest risk: a momentum unwind in a 3.93-beta small cap priced far above every fundamental anchor in the file.
Provenance & disclosures
- Traceability: 0 KB claims, 0 voices — a
grepof the labeled KB returns no MXL entries, sokb_breadth: 0,kb_claim_count: 0, andkb_net_conviction: null(nothing to aggregate; fabricated conviction is structurally impossible). Conviction rating Low by construction; every figure in this note reconciles toscripts/deepdive/pf_data/MXL_data.json. - Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-04-23) · estimates & prices 2026-07-06 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Estimate-basis caveat: FMP consensus EPS for MXL is on a non-GAAP basis (positive) while the consensus EBITDA/EBIT rows are negative through 2028 — a basis inconsistency in the feed; we use the EPS line and disregard the EBITDA rows.
- Earnings-quality caveat: GAAP results include a $26.5M Q1'26 tax charge and ~10.4%-of-revenue stock comp; the non-GAAP↔GAAP gap is large — underwrite cash and non-GAAP trends, but respect that GAAP is still a loss.
- Geography caveat: the geographic segment data on our plan is stale (FY2018); Asia-concentration commentary is historical, not current-year.
- Peer caveat: the FMP-supplied peer list omits the relevant communications-semi comps (Broadcom, Marvell, Semtech, Credo); judge against that cohort.
- Guidance gap: no management-guidance or transcript ingestion for MXL on our plan.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").